AI-driven biopharmaceutical innovator BioMap has recently declared the successful closure of its Series A+ funding round, propelling the cumulative amount raised in its Series A financing to surpass US$100 million. This latest funding initiative was spearheaded by China Life Capital, with unwavering backing from established investors like Shanghai Biomedicine Fund and Fortune Capital. Additionally, it saw contributions from a diverse array of institutions and top-tier enterprises within the biopharmaceutical sector. Index Capital persisted in its role as the sole financial advisor for this round.

The capital garnered will be predominantly allocated towards the continual refinement of two pioneering microscopic world models: the GeoFlow molecular model and the GeoCell cellular model. Furthermore, it will support the expansion of high-throughput automated laboratories and the commercialization endeavors of its proprietary drug development pipelines.

BioMap has forged a cross-scale model framework that seamlessly integrates molecular and cellular dimensions. Notably, the GeoFlow model has undergone three significant generational advancements within a mere two-year span. The anticipated V4 iteration is projected to exhibit marked enhancements in precision for core tasks when juxtaposed with its V3 predecessor. The GeoCell model, on the other hand, excels at simulating cellular reactions under various perturbations, encompassing three pivotal facets of drug discovery: target identification, indication selection, and patient stratification.

Moreover, the company has pioneered the RSI dry-wet closed-loop system to foster the iterative, autonomous evolution of its models. Presently, BioMap boasts a robust portfolio of dozens of in-house drug development pipelines, with several bispecific antibody candidates poised to advance to the IND (Investigational New Drug) phase by 2027.

In the realm of synthetic biology, BioMap has achieved pilot-scale production for more than five product pipelines. A notable milestone is the world's inaugural biosynthetic production of natural borneol, which has slashed costs by 80% relative to traditional plant extraction methods. The company is now primed for large-scale production and anticipates substantial revenue generation by 2027.

Investors maintain a bullish outlook on BioMap's technological strategy and growth prospects, confident that this latest funding infusion will expedite the company's trajectory towards ushering in a new era of superintelligence in the life sciences domain.